Fervent Pharmaceuticals yalengeza lero kuti yayamba maphunziro ake azachipatala kuti awone momwe bukuli limagwirira ntchito pochiza zizindikiro za kutentha pang'ono kapena kutentha kwambiri, kutuluka thukuta usiku komanso kudzutsidwa usiku chifukwa cha kutentha. Mankhwalawa amapangidwa kuti apezeke, ngati avomerezedwa ndi FDA, kwa odwala popanda kufunikira kwa mankhwala. Maphunziro akutali awa ndi amodzi mwa oyamba amtundu wake ovomerezedwa ndi FDA. Odwala mu kafukufukuyu atenga nawo mbali patali ndi chitonthozo cha nyumba zawo, komwe zinthu zonse zofufuzira zidzaperekedwa, komanso komwe kusonkhanitsa deta kudzachitikira.
M2S Hot Flash Study idapangidwa kuti iziphatikiza azimayi omaliza kusamba komanso osiya kusamba azaka zopitilira 45 omwe amakumana ndi 7 mpaka 8 zotentha pang'ono kapena zotentha kwambiri patsiku. Amayi omwe akwaniritsa izi atha kugwiritsa ntchito pa www.m2shotflashstudy.com kuti awaganizidwe kuti achite nawo kafukufukuyu.
"Ndili wokondwa ndi zomwe tikufufuza komanso mwayi womwe ungakhale nawo pakusintha moyo wa odwalawa. Komanso, kukhala ndi dongosolo lophunzirira lomwe limapangitsa kuti anthu azitenga nawo mbali mwachindunji m'nyumba za odwala amalola odwala ambiri kutenga nawo mbali, ndikuchita izi pamadongosolo awo," adatero George Royster, Woyambitsa/CEO wa Fervent Pharmaceuticals. "Ndife okondwa kwambiri kuti kafukufukuyu akuchitika ndikusintha miyoyo ya amayi pogwiritsa ntchito njira zatsopano zochizira matenda osiya kusamba."
Kuyesa kwa milungu itatu kukuperekedwa kwa omwe ali oyenerera m'dziko lonselo. Ophunzira adzafunsidwa kuti azitsatira zizindikiro zawo za vasomotor pa intaneti panthawi ya mayesero ndikumaliza kafukufuku kumapeto kwa phunzirolo. Zopangira zofufuzira zomwe ziyenera kuperekedwa zikuphatikiza mankhwala opangidwa pakamwa, osatulutsa mahomoni, osagwiritsa ntchito mankhwala azitsamba, osakhala a antidepressant a pawiri omwe amadziwika ndi njira zogwirira ntchito, omwe amagwiritsidwa ntchito kale powonetsa zina, ndipo akhala ndi mbiri yakale yogwiritsidwa ntchito motetezeka. . Zida zoyeserera ziphatikizanso zida zophunzitsira kuti aphunzitse ophunzira momwe angagwiritsire ntchito pulogalamu ya kafukufuku wa odwala.
Fervent Pharmaceuticals ndi kampani yopanga mankhwala osokoneza bongo yomwe idakhazikitsidwa ku North Carolina mchaka cha 2011. Imayang'ana kwambiri pakukweza moyo wa amayi popanga njira zochiritsira zomwe zimayang'ana zosowa zosakwanira paumoyo wa amayi.
ZOMWE MUNGACHITE PA NKHANIYI:
- The investigational products to be provided include an orally dosed, non-hormonal, non-herbal, non-antidepressant formulation of a compound that has known mechanisms of action, is already widely used for a different indication, and has a long history of safe use.
- The M2S Hot Flash Study is designed to include peri-menopausal and post-menopausal women over the age of 45 who experience at least 7 to 8 moderate to severe hot flashes per day.
- Fervent Pharmaceuticals announced today that it has commenced its virtual clinical study to evaluate the effectiveness of its novel product for the treatment of the symptoms of moderate to severe hot flashes, night sweats and nighttime awakenings due to hot flashes.
